2. Search Result
Search Result
Results for "

monoclonal

" in MedChemExpress (MCE) Product Catalog:

1721

Inhibitors & Agonists

3

Screening Libraries

20

Fluorescent Dye

6

Biochemical Assay Reagents

15

Peptides

3

MCE Kits

1717

Inhibitory Antibodies

1

Natural
Products

5

Recombinant Proteins

3

Isotope-Labeled Compounds

5

Antibodies

1

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9919
    Durvalumab
    5+ Cited Publications

    MEDI 4736

    		 PD-1/PD-L1 Cancer
    Durvalumab (MEDI 4736) is an human anti-PD-L1 monoclonal antibody . Durvalumab (MEDI4736) completely blocks the binding of PD-L1 to both PD-1 and CD80, with IC50s of 0.1 and 0.04 nM, respectively .
    Durvalumab
  • HY-P9906A
    Bevacizumab (Anti-VEGFA)
    50+ Cited Publications

    		 VEGFR Cancer
    Bevacizumab, a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity .
    Bevacizumab (Anti-VEGFA)
  • HY-P99380
    Zanidatamab
    1 Publications Verification

    ZW 25; ZW-49 Antibody

    		 EGFR Cancer
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
    Zanidatamab
  • HY-P99491
    Camoteskimab
    1 Publications Verification

    AVTX-007; CERC-007; MEDI 2338

    		 Interleukin Related Inflammation/Immunology
    Camoteskimab is a fully human monoclonal antibody with high affinity targeting IL-18. Camoteskimab is applicable to the research of autoinflammatory diseases .
    Camoteskimab
  • HY-108730
    Avelumab
    5+ Cited Publications

    Anti-Human PD-L1, Human Antibody; MSB 0010718C; MSB0010718C

    		 PD-1/PD-L1 Inflammation/Immunology Cancer
    Avelumab (Anti-Human PD-L1) a fully human IgG1 anti-PD-L1 monoclonal antibody (mAb) with potential antibody-dependent cell-mediated cytotoxicity (ADCC). Avelumab enhances ADCC on several cancer cell lines expressing PD-L1. Avelumab can be used for the study of chordoma .
    Avelumab
  • HY-114377
    p-SCN-Bn-DOTA
    1 Publications Verification

    		 Radionuclide-Drug Conjugates (RDCs) Cancer
    p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunoresearch of tumor .
    p-SCN-Bn-DOTA
  • HY-P99269
    Sibrotuzumab
    1 Publications Verification

    BIBH 1; Anti-Human FAP Recombinant Antibody

    		 FAP Cancer
    Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC) .
    Sibrotuzumab
  • HY-P9919A
    Durvalumab (anti-PD-L1)
    5+ Cited Publications

    MEDI 4736 (anti-PD-L1)

    		 PD-1/PD-L1 Cancer
    Durvalumab (anti-PD-L1)(MEDI 4736) is a human anti-PD-L1 protein monoclonal antibody. Durvalumab (anti-PD-L1) completely blocks PD-L1 binding to PD-1 and CD80, IC 50 are 0.1 and 0.04 nM respectively, has anti-tumor activity .
    Durvalumab (anti-PD-L1)
  • HY-P99405
    Prasinezumab

    PRX 002; RG 7935; RO 7046015

    		 α-synuclein Neurological Disease
    Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody directed against aggregated α-synuclein. Prasinezumab has the potential for Parkinson's disease research .
    Prasinezumab
  • HY-P99042
    Polatuzumab
    2 Publications Verification

    		 Transmembrane Glycoprotein ADC Antibody Cancer
    Polatuzumab is a monoclonal antibody that targets CD79b on the surface of B cells. Polatuzumab can be used to synthesize the ADC Polatuzumab Vedotin (HY-132253), which has anti-tumor activity .
    Polatuzumab
  • HY-P99509
    Zelminemab

    AMG-301

    		 Adenylate Cyclase Neurological Disease
    Zelminemab (AMG-301) is a humanized monoclonal antibody that inhibits PACAP type I (PAC1) receptor .
    Zelminemab
  • HY-P99854
    Disitamab
    1 Publications Verification

    RC48-0

    		 EGFR ADC Antibody Cancer
    Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
    Disitamab
  • HY-P99329
    Vadastuximab

    Anti-Human CD33 Recombinant Antibody

    		 Transmembrane Glycoprotein Cancer
    Vadastuximab (Anti-Human CD33 Recombinant Antibody) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine .
    Vadastuximab
  • HY-P99201
    Zilovertamab
    2 Publications Verification

    UC-961; Cirmtuzumab

    		 ROR Wnt Cancer
    Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling .
    Zilovertamab
  • HY-P99616
    Felzartamab

    MOR-202

    		 CD38 Cancer
    Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research .
    Felzartamab
  • HY-P9922
    Olaratumab

    IMC-3G3; LY3012207

    		 PDGFR Cancer
    Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity .
    Olaratumab
  • HY-P99246
    Bermekimab

    MABp1

    		 Interleukin Related Inflammation/Immunology Cancer
    Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis .
    Bermekimab
  • HY-P99904
    Siplizumab

    MEDI-507; TCD601

    		 CD2 Inflammation/Immunology Cancer
    Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody against CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells .
    Siplizumab
  • HY-P99631
    Garadacimab
    1 Publications Verification

    CSL312

    		 Factor Xa Cardiovascular Disease
    Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
    Garadacimab
  • HY-P99232
    Indusatumab

    5F9 monoclonal antibody; TAK-164 Antibody

    		 Guanylate Cyclase ADC Antibody Cardiovascular Disease Cancer
    Indusatumab (5F9 Monoclonal antibody) is a monoclonal antibody against human GUCY2C (Guanylate cyclase 2C). Indusatumab fails to bind to granulocytes or erythrocytes. Indusatumab can be used to synthesize ADCs, such as Indusatumab vedotin (HY-P99662). Indusatumab can be used in cancer research .
    Indusatumab
  • HY-P99936
    Elgemtumab

    LJM716

    		 EGFR Cancer
    Elgemtumab(LJM716) is a fully human IgG monoclonal antibody. Elgemtumab can specifically bind to HER3, block ligand-dependent and independent HER3 signal transduction and cell proliferation, and has good anti-tumor potential .
    Elgemtumab
  • HY-P99271
    Tisotumab

    Anti-Human F3 Recombinant Antibody

    		 ADC Antibody Cancer
    Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody and ADC antibody. Tisotumab targets tissue factor (TF). Tisotumab can be used to synthesize antibody-drug conjugates (ADCs) targeting tissue factor (TF), Tisotumab vedotin (HY-152963). Tisotumab can be used for the research of solid tumors .
    Tisotumab
  • HY-P99850
    Depemokimab

    GSK-3511294

    		 Interleukin Related Inflammation/Immunology
    Depemokimab (GSK-3511294) is a long-acting anti-IL-5 monoclonal antibody. Depemokimab can be used for research of asthma .
    Depemokimab
  • HY-P99423
    Adintrevimab
    2 Publications Verification

    ADG 20

    		 SARS-CoV Infection
    Adintrevimab (ADG 20) is a human IgG1 monoclonal SARS-CoV (SARS-CoV) antibody. Adintrevimab inhibits SARS-CoV-2 variants and other SARS-like coronaviruses with pandemic potential .
    Adintrevimab
  • HY-P99453
    Azintuxizumab

    		ADC Antibody Cancer
    Azintuxizumab is an anti-SLAMF7 human IgG4κ monoclonal antibody. Azintuxizumab can be used in the synthesis of antibody-drug conjugate (ADC), Azintuxizumab vedotin .
    Azintuxizumab
  • HY-P99556
    Tixagevimab

    AZD8895; COV2-2196

    		 SARS-CoV Infection
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor .
    Tixagevimab
  • HY-P9969
    Matuzumab

    EMD 72000

    		 EGFR Cancer
    Matuzumab (EMD 72000) is a humanized anti-EGFR monoclonal antibody that blocks EGFR activation and downstream signaling, inhibits tumor growth. Deglycosylation and the possible elimination of ADCC activity can reduce the in vivo anti-tumor activity of Mattuzumab .
    Matuzumab
  • HY-P99210
    Olokizumab
    1 Publications Verification

    CDP 6038; OKZ

    		 Interleukin Related STAT Inflammation/Immunology Endocrinology
    Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis .
    Olokizumab
  • HY-P99169
    Uliledlimab

    TJ004309

    		 CD73 Cancer
    Uliledlimab is a potent against CD73 humanizedized monoclonal antibody. Uliledlimab inhibits the conversion of extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab can be used in research of cancer .
    Uliledlimab
  • HY-P991271
    NN-8828

    NNC-114-0005

    		 Interleukin Related Inflammation/Immunology
    NN-8828 (NNC-114-0005) is a humanized monoclonal antibody inhibitor targeting interleukin-21 (IL-21). NN-8828 is promising for research of immune system diseases .
    NN-8828
  • HY-P99295
    Imgatuzumab

    RG 7160; RO 5083945; Anti-EGFR Recombinant Antibody

    		 EGFR Cancer
    Imgatuzumab (RG 7160) is a humanized monoclonal antibody against the EGFR. Imgatuzumab acts as an immunomodulator. Imgatuzumab can be used in research of cancer .
    Imgatuzumab
  • HY-P991290
    IRAB-B

    		Insulin Receptor Metabolic Disease Inflammation/Immunology Endocrinology
    IRAB-B is a human monoclonal antibody targeting INSR. IRAB-B is an insulin receptor (IR) antagonist and can be used in the study of insulin resistance and diabetes .
    IRAB-B
  • HY-P99779
    Plonmarlimab

    TJ003234; TJM2

    		 c-Fms SARS-CoV Infection Inflammation/Immunology
    Plonmarlimab (TJ003234) is an anti-GM-CSF monoclonal antibody. Plonmarlimab can be used for research of rheumatoid arthritis and COVID-19 .
    Plonmarlimab
  • HY-P99538
    Ublituximab

    LFB-R603; TG-1101; TGTX-1101

    		 CD20 Cancer
    Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects .
    Ublituximab
  • HY-P99514
    Zalifrelimab

    AGEN1884

    		 CTLA-4 Cancer
    Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody targeting CTLA-4 (CTLA-4). Zalifrelimab antagonizes the inhibitory checkpoints of immune cell activation regulated by CTLA-4 signaling .
    Zalifrelimab
  • HY-P990766
    Sipavibart

    AZD3152

    		 SARS-CoV Infection
    Sipavibart (AZD3152) is a human IgG1 λ2 monoclonal antibody against SARS-CoV-2. Sipavibart is applicable to research related to COVID-19. The isotype control product for Sipavibart is Human IgG1 lambda2, Isotype Control (HY-P990096) .
    Sipavibart
  • HY-P99643A
    Ginisortamab (Mouse IgG1)

    		Dan family Cancer
    Ginisortamab (Mouse IgG1) is the anti-Gremlin-1 monoclonal antibody with mouse IgG1. Ginisortamab (Mouse IgG1) can be used in research of gastrointestinal (GI) tumors .
    Ginisortamab (Mouse IgG1)
  • HY-P99628
    Futuximab

    		EGFR Cancer
    Futuximab is a chimeric monoclonal antibody targeting non-overlapping epitopes on EGFR. Futuximab has antineoplastic activity .
    Futuximab
  • HY-P99425
    Afelimomab

    MAK 195F

    		 TNF Receptor Infection Inflammation/Immunology
    Afelimomab (MAK 195F) is an anti-tumor necrosis factor monoclonal antibody. Afelimomab can be used for the research of sepsis .
    Afelimomab
  • HY-P99474
    Bertilimumab

    CAT 213; iCo-008

    		 CCR Inflammation/Immunology
    Bertilimumab (CAT 213; iCo-008) is a human monoclonal antibody targeting eotaxin-1 (CCL11). Bertilimumab has the potential for allergic disorders research .
    Bertilimumab
  • HY-P99409
    Oregovomab

    Alt-2 monoclonal antibody; MAB-B43.13; Oregovamab

    		 Transmembrane Glycoprotein Cancer
    Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells .
    Oregovomab
  • HY-P991694
    Latarcibart

    VGA-039

    		 Factor VIII Cardiovascular Disease
    Latarcibart is an anti-protein S monoclonal antibody.Latarcibart can be used for the research of bleeding disorders .
    Latarcibart
  • HY-P99854A
    Disitamab (powder)
    1 Publications Verification

    RC48-0 (powder)

    		 EGFR ADC Antibody Cancer
    Disitamab (RC48-0) (powder) is a humanized monoclonal antibody targeting HER2. Disitamab (powder) can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985) .
    Disitamab (powder)
  • HY-P99624
    Foravirumab

    CR4098

    		 RABV Infection
    Foravirumab (CR4098) is a monoclonal antibody against rabies virus glycoprotein antigenic site III .
    Foravirumab
  • HY-P99760
    Nurulimab

    BCD-145

    		 CTLA-4 Cancer
    Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma .
    Nurulimab
  • HY-156035
    Bz-DTPA
    1 Publications Verification

    		 Biochemical Assay Reagents Inflammation/Immunology
    Bz-DTPA is a bifunctional chelator. Bz-DTPA can be used for preparing immunoconjugate of monoclonal antibody 2G3 labeled with indium-111 .
    Bz-DTPA
  • HY-P99702
    Levilimab

    BCD-089

    		 Interleukin Related Inflammation/Immunology
    Levilimab (BCD-089) is a fully humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody. Levilimab is an inflammation-alleviating antibody. Levilimab can be used for the research of rheumatoid .
    Levilimab
  • HY-P991225
    BI-1206

    		Fc Receptor (FcR) CD20 Inflammation/Immunology Cancer
    BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
    BI-1206
  • HY-P99695
    Lerdelimumab

    CAT-152

    		 TGF-beta/Smad Neurological Disease
    Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research .
    Lerdelimumab
  • HY-P99825
    Relfovetmab

    		TNF Receptor Neurological Disease Inflammation/Immunology
    Relfovetmab is an anti-NGF monoclonal antibody (mAb) .
    Relfovetmab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: